Gynostemma pentaphyllum for dyslipidemia: A systematic review of randomized controlled trials.
- 2022-08-26
- Systematic Review
- Frontiers in pharmacology 13
- Ning Dai
- Fang-Fang Zhao
- Min Fang
- Feng-Lan Pu
- Ling-Yao Kong
- Jian-Ping Liu
- PubMed: 36091752
- DOI: 10.3389/fphar.2022.917521
- High evidence
- Clinical
GP plus lipid-lowering agents were superior to lipid-lowering agents in TG (MD -0.65 mmol/L, 95% CI -1.03 to -0.28), LDL-C (MD -0.57 mmol/L, 95% CI -1.07 to -0.08), and HDL-C (MD 0.15 mmol/L, 95% CI 0.11-0.20).
- Effect
- Beneficial
- Effect size
- Moderate
- Significant
- Yes